The FDA now allows "no artificial colors" labeling claims for foods without FD&C-certified synthetic colors, part of federal efforts to transition away from petroleum-based dyes. The agency approved beetroot red and expanded spirulina extract uses while initiating a safety review of preservative BHA.
An FDA advisory panel unanimously recommended approval of Moderna's mRNA flu vaccine mFlusiva for adults 50 and older. The vaccine showed a 27% reduction in flu cases versus a standard shot. A final FDA decision is expected by early August.
HHS and CMS issued a proposed rule to codify the Medicare Drug Price Negotiation Program, largely formalizing existing guidance. The rule includes new provisions, such as clarifications for new drug formulations. The proposal is now open for public comment.
The FDA pulled back publication of several studies on COVID-19 and shingles vaccines. The blocked studies involved millions of patient records, and two COVID-19 papers were withdrawn in October 2025.
The Fifth Circuit reinstated an in-person dispensing requirement for mifepristone, blocking telemedicine prescriptions. The ruling came after a federal judge paused Louisiana's lawsuit pending the FDA's safety review of the abortion medication.
US health policy activity this week included HHS FY 2027 budget hearings, a House review of Medicare fraud and bipartisan discussion of PBM reform. President Trump also issued an executive order on mental illness treatments, and CMS and FDA announced the RAPID pathway.
The acting director of the CDC delayed publication of a report showing the COVID-19 vaccine cut emergency department visits and hospitalizations for healthy adults last winter by about half. The Department of Health and Human Services did not immediately respond to request for comment.
mRNA cancer vaccines showed promising pancreatic cancer trial results and boosted tumor-fighting drugs in other research. U.S. officials canceled $500 million in vaccine funding, while the NCI is backing a $200 million cancer vaccine partnership.
The FDA has expanded animal drug options for New World screwworm through conditional approvals and emergency use authorizations. The agency lists products for cattle, dogs and cats and says its guidance page will be updated as more drugs move through the system.
NIH funded dramatically fewer research grants in 2025, with funding rates dropping from 27% to 20% for established investigators and from 26% to 19% for early-career researchers, according to newly released agency data.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07478471 |
Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax |
NOT_YET_RECRUITING | |
| NCT07446647 |
Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion |
RECRUITING | PHASE1 |
| NCT07390955 |
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 |
RECRUITING | PHASE1 |
| NCT07204444 |
The BE WITH Project: A Partially Nested Randomized Control Trial (PN-RCT) |
COMPLETED | NA |
| NCT07001254 |
UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia |
NOT_YET_RECRUITING | PHASE2 |
| NCT06990724 |
Effectiveness Testing of a Videogame Intervention (No Baby No) to Decrease Contraception Non-use Among Adolescents. |
RECRUITING | NA |
| NCT06919016 |
A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06905275 |
A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV |
SUSPENDED | PHASE1 |
| NCT06812494 |
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV |
RECRUITING | PHASE2 |
| NCT06694376 |
Understanding and Expanding the Reach of Home Visiting (HV-REACH) Project |
NOT_YET_RECRUITING |
